Placebo to match FF/UMEC/VI

DRUG4 trials

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 3

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT02345161

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2015-01-23End: 2016-04-07Updated: 2018-07-13

Phase 4

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03474081

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-03-29End: 2019-07-17Updated: 2021-07-15

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03478696

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-06-25End: 2019-03-18Updated: 2020-10-28

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03478683

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-06-25End: 2019-03-14Updated: 2020-10-28

American Journal of Respiratory and Critical Care Medicine2025-05-01

Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World Data.

2021-04-1215 citations

Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.

2020-07-1011 citations

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.

2020-07-097 citations

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.

2020-05-2930 citations

P244 Defining the minimum clinically important difference (MCID) for the evaluating respiratory symptoms in COPD daily diary using global anchors: data from the FULFIL study

2018-11-16

Preventing clinically important deterioration with single-inhaler triple therapy in COPD

ERJ Open Research2018-10-0125 citations

Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain

2018-09-15

Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β<sub>2</sub>-Agonist Therapy: An Integrated Post Hoc Analysis.

2018-09-0612 citations

Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.

2018-01-0818 citations

P272 Improvements in exacerbation rates with single inhaler triple therapy versus dual ics/laba therapy in patients with advanced chronic obstructive pulmonary disease (copd): subgroup analyses of the phase iii fulfil study

2017-11-152 citations

Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.

2017-09-0512 citations

Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses

2017-09-013 citations

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease

American Journal of Respiratory and Critical Care Medicine2017-04-04323 citations

LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial

2016-09-011 citations

Placebo to match FF/UMEC/VI

Sponsors

Conditions

Phase 3

Phase 4

Related Papers